The in vivo thrombolytic efficacy of Δ(K2-K5) plasmin was established in rabbit and canine thrombosis models because larger animals better accommodated the dosing requirements of direct acting thrombolytic agents. The gene discussed is PLG; the disease is deep vein thrombosis.